Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  aldesleukin
Find trials that include:  Any drugs shown
Results 1-25 of 52 for your search:
Start Over
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: 12PLK02, NCI-2013-01697, NCT01856023
Isotretinoin with or without Dinutuximab, Aldesleukin, and Sargramostim following Stem Cell Transplant in Treating Patients with Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and under at diagnosis
Trial IDs: ANBL0032, NCI-2009-01064, CDR0000069018, COG-ANBL0032, COG-P9842, NCT00026312
Entinostat in Combination with Aldesleukin in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 145208, NCI-2012-02900, CDR0000662915, NCI 7870, NCT01043159, RPCI #23, 7870, NCT01038778
Genetically Modified T Cells, Aldesleukin, and Combination Chemotherapy in Treating Patients with Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0013, NCI-2013-01468, 1004-1036, 110013, 344344, P10648, RD-10-IV-02, NCT01218867
Ipilimumab, Combination Chemotherapy, and Biological Therapy in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2011-0073, NCI-2011-02768, NCT01409174
Genetically Modified T Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0266, NCI-2013-01508, 110266, 1103-1095, P11810, RD-11-III-06, NCT01454596
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 11-080, 1302010628, NCT01550367
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, NCT01640301
Umbilical Cord Blood-Derived Natural Killer Cells, Lenalidomide, High-Dose Melphalan, and Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 2011-0379, NCI-2014-01096, NCI-2014-00541, RV-MM-PI-0691, NCT01729091
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients with Stage III or Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 14 and over
Trial IDs: 2009-0471, NCI-2014-02655, NCT01740557
Viral oncoprotein targeted autologous T cell therapy for Merkel cell carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2586.00, NCI-2012-02779, 2586, NCT01758458
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
Gene Therapy in Treating Patients with Metastatic or Locally Advanced Cancer That Is Recurrent or Refractory
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0052, NCI-2014-02650, 1310-1253, 140052, P131408, RD-13-X-03, NCT02111850
Genetically Engineered Lymphocytes and Aldesleukin after Cyclophosphamide and Fludarabine Phosphate in Treating Patients with Metastatic or Locally Advanced Refractory/Recurrent Cancer That Expresses MAGE-A3
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0110, NCI-2014-02496, 1402-1293, 338101, P131467, RD-14-III-03, NCT02153905
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
T-cell Receptor Gene Therapy Targeting HPV-16 E6 in Treating Patients with Metastatic, Recurrent, or Refractory HPV-Related Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0005, NCI-2014-02319, 1407-1331, 337514, P141607, RD-14-VIII-09, NCT02280811
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy in Treating Patients with Metastatic Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, P09567, NCT01174121
Combination Chemotherapy, Rituximab, Methylprednisolone, and Allogeneic Natural Killer (NK) Cells for Treating Patients With Refractory Lymphoid Malignancies
Phase: Phase II
Type: Treatment
Age: not specified
Trial IDs: MT2009-15, NCI-2010-00228, 2009LS083, NCT01181258
Aldesleukin with or without Ziv-Aflibercept in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: PhII-107, NCI-2011-02498, CDR0000690654, CHNMC-PHII-107, 8628, NCT01258855
Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin after Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Refractory Human Papilloma Virus-Associated Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0116, NCI-2013-01524, 120116, 12C0116-H, 327146, P11943, NCT01585428
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin in Treating Patients With High-Risk Neuroblastoma Previously Treated With High-Dose Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 8 and under
Trial IDs: DIV-NB-201, NCI-2012-01336, CDR0000733747, 9347, NCT01592045
Decitabine, Vorinostat, and Donor Natural Killer Cells in Treating Patients with High-Risk Myelodysplastic Syndromes
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: MT2012-04, NCI-2012-01320, 1204M13602, 2011LS124, NCT01593670
Start Over